Quarterly ResultMay 11, 2026, 04:06 PM
Skye Bioscience Q1 Net Loss $12.5M; Going Concern Doubt; Nasdaq Deficiency
AI Summary
Skye Bioscience reported a net loss of $12.5 million for Q1 2026, an increase from $11.1 million in Q1 2025, driven by higher R&D and G&A expenses. The company disclosed substantial doubt about its ability to continue as a going concern beyond Q4 2026 without additional funding, despite having sufficient capital until then for current operations. Additionally, Skye Bioscience received a Nasdaq deficiency notice for its common stock trading below $1.00 per share, with a compliance deadline of September 14, 2026. The company also faces ongoing legal proceedings, including the Cunning Lawsuit with an estimated contingency of $2.6 million.
Key Highlights
- Net loss increased to $12.5 million in Q1 2026 from $11.1 million in Q1 2025.
- Substantial doubt about going concern beyond Q4 2026 without additional funding.
- Received Nasdaq deficiency notice for bid price below $1.00; compliance by Sep 14, 2026.
- Research and development expenses rose to $7.9 million from $7.2 million YoY.
- General and administrative expenses increased to $4.7 million from $4.6 million YoY.
- Cash and cash equivalents were $8.1 million as of March 31, 2026.
- Total current assets decreased to $18.6 million from $27.1 million since Dec 31, 2025.
- Estimated legal contingency for Cunning Lawsuit is $2.6 million.